RxDoctor Payments Data

Jonathan Lenzen

Critical Care Medicine · Jasper, TNNPI 1275502510

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.7% of the total across 107 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AstraZeneca at 36.8% of the total. 2023 is the largest year on record at $689, 2.7 times the $252 reported in 2019.

$2,262in general payments, 2019–2025

Across 107 payments — averaging $21.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$832
  • GSK$358
  • Sunovion Pharmaceuticals Inc.$249
  • Grifols USA, LLC$221
  • Takeda Pharmaceuticals U.S.A., Inc.$173
  • Boehringer Ingelheim$75
  • plus $354 from 11 others

What the payments were for

  • Food & beverage$2,21198%
  • Education$512%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,262 in reported general payments places this provider in the 75th percentile of 141 critical care medicine providers in Tennessee.

See all critical care medicine providers in Tennessee

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate12$158,821
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$21,701
Albuterol Sulfate HfaAlbuterol Sulfate45$1,178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev$75$158,82112 claims
GSKTrelegy Ellipta$358$21,70132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 141 critical care medicine providers in Tennessee.

Other critical care medicine in Jasper

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →